FDA Reopens Comment Period on Financial Disclosure Rule for Clinical Investigators, to be Discussed at Open Meeting

Summary

The FDA is reopening the comment period for its proposed rule on financial disclosure by clinical investigators and will hold an open meeting to discuss the rule, which was first published in 1994, to gather additional feedback on eliminating a provision related to significant payments.